Clinical Trials Logo

Filter by:
NCT ID: NCT01332812 Completed - Clinical trials for Postoperative Cognitive Dysfunction

Dexamethasone for the Prevention of Postoperative Cognitive Dysfunction

Start date: January 2011
Phase: Phase 4
Study type: Interventional

This study aims to evaluate the possible effect of dexamethasone on prevention of cognitive dysfunction in the postoperative period of elderly patients undergoing to surgery under general anesthesia.

NCT ID: NCT01332071 Completed - Clinical trials for Diabetes Mellitus, Type 2

Avandamet Bioequivalence Study Brazil - Fed Administration

Start date: November 2009
Phase: Phase 1
Study type: Interventional

The study is prospective, open-label, randomized, crossover, with 02 treatments, 02 sequences, and 02 periods. The volunteers received, in each period, the reference or the test formulation after standardized meals.

NCT ID: NCT01331850 Completed - Clinical trials for Hepatitis C, Chronic

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Start date: May 2011
Phase: Phase 2
Study type: Interventional

This randomized, open-label, multi-center study will evaluate the sustained virological response, pharmacokinetics and safety of various combinations of danoprevir/ritonavir with Copegus plus RO5024048 and/or Pegasys in patients with chronic hepatitis C infection. Patients will be divided into 2 separate cohorts. Cohort A, previous partial responders, will be randomized to Groups 1-3 and cohort B, previous null responders, will be randomized to Groups 4-6. Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Groups 1 and 4 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks; Group 2 will receive Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks; Groups 3, 5 and 6 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks. In addition, patients in Group 6 will receive another 24 weeks of Pegasys plus Copegus treatment.

NCT ID: NCT01331538 Completed - Clinical trials for Temporomandibular Dysfunction

Temporomandibular Dysfunction and Cervical Posture

Start date: February 2009
Phase: N/A
Study type: Observational

The aim of this research was to determine the existence of a correlation between the degree of temporomandibular dysfunction and cervical posture in different occlusal classes in adolescents. A cross-section, observational study was carried out, in which 296 adolescents took part. For the evaluation, the patients were divided into groups according to the presence and severity of the temporomandibular dysfunction, using a questionnaire and occlusal Angle classification. The posture analysis was carried out using photogrammetry and the software Alcimage® to measure the predefined angle based on the protuberances of the Spinous Process of the 7th Cervical Vertebra (C7), Manubrium of the sternum and Mentum Vertex.

NCT ID: NCT01331369 Completed - Clinical trials for Medication Adherence

Intensification of Care to Improve Adherence to Anti-hypertensives

HyperCare
Start date: November 2010
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the effectiveness of a social-psychological intervention to improve anti-hypertensives adherence in primary care. Its is a pragmatic clinical trial.

NCT ID: NCT01331031 Completed - Adolescent Behavior Clinical Trials

Parafunctional Habits and Temporomandibular Disorder in Adolescents

Start date: February 2008
Phase: N/A
Study type: Observational

The disorders that affect the temporomandibular joint (TMJ) are responsible for the diverse symptoms. Objective: To evaluate whether or not the relationship between signs or symptoms of TMD and presence of harmful habits. The investigators evaluated 244 adolescents enrolled in public school . The investigators used the questionnaire for selection of orofacial pain and temporomandibular disorders, recommended by American Academy of Orofacial Pain to assess the presence or absence of signs and symptoms of TMD.

NCT ID: NCT01330394 Completed - Alcohol Dependence Clinical Trials

Transcranial Direct Current Stimulation Over Dorsolateral Prefrontal Cortex in Alcoholism

Start date: June 2011
Phase: Phase 2
Study type: Interventional

Alcohol dependency is the most frequent addiction leading to a massive burden of both, patients health, and economy. Present therapeutic concepts suffer from limited efficacy, and thus new innovative therapies are needed. Neuroscientific studies have shown that prefrontal function in alcohol-dependent patients is impaired, leading to cognitive disturbances, and continuation of dependent behaviour. The results of pilot studies demonstrate that activation of prefrontal cortices via non-invasive brain stimulation improves cognitive performance in healthy subjects, and diminishes dependency-related behaviour in patients. The investigators aim to develop a stimulation protocol suited to induce a clinically relevant improvement of prefrontal functions in patients suffering from alcohol dependency. Therefore, the investigators will develop stimulation protocols which are able to modulate prefrontal activation for a much longer time course than those currently available, and will explore if the induced physiological alterations translate to respective cognitive improvements and reduction of addictive behaviour.

NCT ID: NCT01330303 Completed - Healthy Volunteers Clinical Trials

SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin

Start date: December 2009
Phase: Phase 1
Study type: Interventional

It will be an open-label, randomized, laboratory-blind, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the volunteers receive, in each period, the test formulation or the reference formulation, under fed conditions.

NCT ID: NCT01329640 Terminated - Clinical trials for Locally Advanced HER2-positive Breast Cancer

Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)

Start date: September 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, effectiveness and cost-effectiveness of metronomic chemotherapy combined with trastuzumab as neoadjuvant therapy for locally advanced HER2-positive breast cancer.

NCT ID: NCT01329627 Terminated - Clinical trials for Locally Advanced HER2-negative Breast Cancer

Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer

TAME-01
Start date: August 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether weekly paclitaxel followed by weekly doxorubicin plus daily oral cyclophosphamide without granulocyte colony-stimulating factor (G-CSF) is feasible in the treatment of locally advanced HER2-negative breast cancer.